Skip to main content

HF diuretic resistance....the causes and management


Diuretic resistance is multifactorial.
  • Patients with heart failure often have some degree of chronic kidney disease.  As previously discussed, loop diuretics reached the tubular lumen by active secretion.  In renal insufficiency, secretion of loop diuretics is reduced.  This is in part because of accumulated, endogenous organic anions, which compete with loop diuretics at the transporter site.  Increased doses of loop diuretics are thus required to overcome this competitive inhibition.  Additionally, renal blood flow may be decreased in states of renal impairment, further interfering with diuretic secretion. Peak urinary concentrations of loop diuretics are reduced and delayed, resulting in a diminished diuretic effect.
  • Non-adherence to sodium restriction can obviate the benefits of loop diuretics.
  • Non-steroidal anti-inflammatory drugs interfere with prostaglandin synthesis and can antagonize the response to loop diuretics.

Resistance management 
Considering the mechanisms of diuretic resistance discussed above, there are 4 strategies to manage diuretic resistance:
  • Ensure adherence to sodium restriction and medical regimen.
  • Escalate the dose of the loop diuretic.  Alternatively, some clinicians favor changing to a different loop diuretic.  For example, bumetanide has better oral bioavailability than furosemide (80% versus 40%, respectively).  Although bumetanide is more potent than furosemide by a factor of 40 based on weight, both drugs should be equally effective in equivalent dosing.
  • Consider changing intravenous bolus injections to continuous infusion of a loop diuretic.  Continuous intravenous infusion has the advantage of maintaining an effective urinary drug concentration and avoiding periods of post-diuresis sodium retention.  An IV drip may be considered if patients with CHF are refractory to 250 mg of furosemide given orally or intravenously (e.g. continuous furosemide infusion of 10 to 20 mg/hr or bumetanide infusion of 0.5 mg/hr).
  • Consider combination diuretic therapy.  At least 3 studies support the use of thiazide diuretics in addition to loop diuretics for patients resistant to high doses of loop diuretics.  Although there was survival benefit to spironolactone in the RALES study, this was not specifically tested in the context of diuretic resistance and CHF.

Comments

Post a Comment

Popular posts from this blog

power injectable peripherally inserted central catheters

Clinical experience with power injectable peripherally inserted central catheters in intensive care patients     Introduction In intensive care units (ICU), peripherally inserted central catheters (PICC) may be an alternative option to standard central venous catheters, particularly in patients with coagulation disorders or at high risk for infection. Some limits of PICCs (such as low flow rates) may be overcome by the use of power-injectable catheters . Method We have retrospectively reviewed all the power injectable PICCs inserted in adult and pediatric patients in the ICU during a 12-month period, focusing on the rate of complications at insertion and during maintenance. Results We have collected 89 power injectable PICCs (in adults and in children), both multiple and single lumen. All insertions were successful. There were no major complications at insertion and no episodes of catheter-related blood stream infection. Non-infective complications ...
1 comment
Read more

The 12 decision making steps for post dural puncture headache treatment

Treatment decision-making algorithm for postdural puncture headache. 1. When diagnosis is made, all patients should receive supportive measures (reassurance, bed rest, analgesics, hydration, quiet environment). 2. Severity of symptoms should be classified using VAS scale (mild 1–3, moderate 4–6, severe 7–10). 3. Virtually all patients will improve in time even without additional therapy. (dashed lines) 4. Symptoms worsen or fail to resolve within 5 days. 5. Patient preference dictates the choice between pharmacologic (less effective) and epidural blood patch (EBP). 6. In patients with severe symptoms, EBP is strongly suggested. 7. The most common pharmacologic measure is  caffeine  prescription. 8. The failure, worsening, or recurrence of symptoms after pharmacologic measures favors the use of EBP. 9. In addition to EBP, other epidural treatment options can be considered in select patients (eg,  dextran , saline). 10. A period of 24 h should lapse before repeating EBP. 11...
1 comment
Read more

Things to Avoid in Anesthesia for Pregnant with Pulmonary hypertension

Anesthesia for Pregnant woman with Pulmonary Hypertension is a real challenge for anesthesiologist. It is very crucial to remember the pathophysiology of pulmonary hypertension in pregnant women and to avoid some practices that will worsen the cardiac status. 1-Avoid single shot spinal anesthesia. Some authorities consider pulmonary hypertension as absolute contraindication for single shot spinal anesthesia specially in patients with NYHA III ,IV. Spinal anesthesia causes major hemodynamic instability(decrease SVR, decrease VR, decrease in CO) The preferred neuroaxial techniques are (epidural anesthesia and CSE with minimal spinal dose) 2-Avoid PAC. Pulmonary Artery catheters insertion may lead to pulmonary artery rupture or thrombosis. TEE is better cardiac monitor/Arteial line is mandatory. 3-Avoid Nitrous oxide in gas mixture.N2O increase the PVR 4-If MV to be started, avoid High TV and PEEP 5-Avoid Oxytocin Boluses, or rapid administration of Pitocin. Oxytocin causes ...
Post a Comment
Read more